

## Critical Review

# Predictive Factors for Toxicity After Primary Chemoradiation for Locally Advanced Cervical Cancer: A Systematic Review

Anouk Corbeau, MSc,\* Wilma D. Heemsbergen, PhD,<sup>†</sup> Sander C. Kuipers, MSc,<sup>†,‡</sup> Jeremy Godart, PhD,<sup>†,‡</sup> Carien L. Creutzberg, MD, PhD,\* Remi A. Nout, MD, PhD,<sup>†</sup> and Stephanie M. de Boer, MD, PhD\*

\*Department of Radiation Oncology, Leiden University Medical Center, Leiden, The Netherlands; <sup>†</sup>Department of Radiotherapy, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands; and <sup>‡</sup>Department of Medical Physics & Informatics, HollandPTC, Delft, The Netherlands

Received Jun 26, 2023; Accepted for publication Nov 4, 2023

**Purpose:** Women with locally advanced cervical cancer (LACC) undergoing primary platinum-based chemoradiotherapy and brachytherapy often experience toxicities. Normal-tissue complication probability (NTCP) models quantify toxicity risk and aid in optimizing radiation therapy to minimize side effects. However, it is unclear which predictors to include in an NTCP model. The aim of this systematic review was to provide an overview of the identified predictors contributing to gastrointestinal (GI), genitourinary (GU), and vaginal toxicities and insufficiency fractures for LACC.

**Methods and Materials:** A systematic search was performed and articles evaluating the relationship between predictors and toxicities in women with LACC treated with primary chemoradiation were included. The Quality In Prognosis Studies tool was used to assess risk of bias, with high-risk studies being excluded from further analysis. Relationships between dose-volume parameters, patient and treatment characteristics, and toxicity endpoints were analyzed.

**Results:** Seventy-three studies were identified. Twenty-six had a low or moderate risk of bias and were therefore included. Brachytherapy-related dose-volume parameters of the GI tract, including rectum and bowel equivalent dose in 2 Gy fractions (EQD2) D2 cm<sup>3</sup>, were frequently related to toxicities, unlike GU dose-volume parameters. Furthermore, (recto)vaginal point doses predicted toxicities. Few studies evaluated external beam radiation therapy dose-volume parameters and identified rectum EQD2 V30 Gy, V40 Gy, and V55 Gy, bowel and bladder EQD2 V40 Gy as toxicity predictors. Also, total reference air kerma and vaginal reference length were associated with toxicities. Relationships between patient characteristics and GI toxicity were inconsistent. The extent of vaginal involvement at diagnosis, baseline symptoms, and obesity predicted GU or vaginal toxicities. Only 1 study evaluated insufficiency fractures and demonstrated lower pretreatment bone densities to be associated.

**Conclusions:** This review detected multiple candidate predictors of toxicity. Larger studies should consider insufficiency fractures, assess dose levels from external beam radiation therapy, and quantify the relationship between the predictors and treatment-related toxicities in women with LACC to further facilitate NTCP model development for clinical use. © 2023 The Author

Corresponding author: Anouk Corbeau, MSc; E-mail: [a.corbeau@lumc.nl](mailto:a.corbeau@lumc.nl)

Disclosures: C.L.C. reports a membership at the IDMC for Merck and the receipt of the Oncentra research platform from Elekta, all outside the submitted work. J.G. reports a membership of the Dutch Society of Medical Physics for radiation therapy outside the submitted work. R.A.N. reports grants from the Dutch Cancer Society, Dutch Research Council, Elekta, and Accuray and the participation in 1 advisory board meeting for Merck, all outside the submitted work. The other authors report no conflicts of

interest outside the submitted work. This study was partly funded by Varian, a Siemens Healthineers Company.

Data Sharing Statement: Research data are stored in an institutional repository and will be shared upon request to the corresponding author.

**Acknowledgments**—The authors thank the Walaeus Library of the LUMC for developing the search strategy.

Supplementary material associated with this article can be found in the online version at [doi:10.1016/j.ijrobp.2023.11.010](https://doi.org/10.1016/j.ijrobp.2023.11.010).

(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>)

## Introduction

The standard treatment for locally advanced cervical cancer (LACC) is definitive chemoradiation treatment combining external beam radiation therapy (EBRT) with concurrent platinum-based chemotherapy, followed by image-guided adaptive brachytherapy (BT).<sup>1</sup> The prospective observational EMBRACE-I study registered patients with LACC who underwent this treatment between 2008 and 2015. The study reported actuarial estimates for severe (grade 3-4) late gastrointestinal (GI), genitourinary (GU), vaginal, and fistula events at 5 years of 8.5%, 6.8%, 5.7%, and 3.2%, respectively.<sup>2</sup> Additionally, a mono-institutional, retrospective study conducted during the same timeframe reported cumulative incidences of severe late bowel, rectal, bladder, and vaginal toxicity of, respectively, 0.8%, 3.3%, 3.6%, and 1.4% over 5 years of follow-up.<sup>3</sup> Moreover, a cumulative incidence of insufficiency fractures of 2.8% was found.<sup>3</sup> Meta-analyses evaluating pelvic insufficiency fractures after radiation therapy for gynecologic cancers demonstrated even a higher pooled incidence estimate, ranging between 9.4% and 15.3%.<sup>4-6</sup> This may be because of heterogeneous strategies of detecting such fractures or it may represent differences in treatment techniques. Despite the excellent 5-year local control in the EMBRACE-I and the retrospective study (between 90.4% and 92%<sup>3,7</sup>), treatment-related side effects were shown to reduce quality of life.<sup>8-13</sup> Furthermore, toxicities may limit the use of more intensified systemic therapy regimens or radiation dose escalation, which are emerging research areas.<sup>14,15</sup>

Advancements in cervical cancer treatment over the last decades, including the introduction of plan-of-the-day strategies, more conformal radiation therapy techniques for EBRT, and magnetic resonance imaging guidance during BT have demonstrated a reduction in toxicity while improving oncological outcomes.<sup>16-19</sup> Planning studies have demonstrated that proton beam radiation therapy (PT) reduces doses to organs at risk even further and thus might be able to decrease the risk of therapy-associated toxicities compared with the current standard-of-care intensity modulated radiation therapy or volumetric-modulated arc therapy.<sup>20-23</sup> Normal-tissue complication probability (NTCP) models quantify the toxicity risk of an individual patient and can therefore serve as a valuable tool for shared decision making, treatment optimization, or the selection of the most beneficial radiation therapy technique, including PT, to minimize toxicity risks.<sup>24,25</sup>

Multifactorial NTCP models should accurately predict treatment-related normal tissue morbidity by combining dosimetric normal tissue parameters and clinical information.<sup>26,27</sup> The majority of the studies perform regression analyses to provide risk factors, reflecting a mere correlation between predictive factors and complications. Clinically applicable NTCP

models for toxicities in cervical cancer treatment are therefore not yet available. Furthermore, the most relevant predictors to include in the NTCP models have to be selected. This could be based on existing literature and clinical reasoning.<sup>26</sup> Even though multiple studies have established relationships between dose-volume parameters or clinical characteristics and toxicity after cervical cancer treatment, a comprehensive overview of predictors is lacking.

This systematic review aims to identify predictive factors for GI toxicity, GU toxicity, vaginal toxicities, and insufficiency fractures in women with LACC treated with definitive chemoradiation, consisting of EBRT, concurrent platinum-based chemotherapy, and image-guided adaptive BT. An overview of candidate predictors will facilitate the future development of NTCP models for clinical use.

## Methods and Materials

### Search strategy

A systematic search was conducted in Web of Science, Embase, Medline, and The Cochrane Library for the period from the 1st of January 1995 to the 1st (The Cochrane Library) or 14th (other databases) of March 2023. The search term consisted of 4 parts, focusing on predictors/model, toxicity, (chemo)radiation therapy, and gynecologic cancer, and can be found in Appendix EA ([Supplementary Materials](#)). First, the references the search yielded were evaluated for duplicates. After removal of duplicates, the reviewers screened the title of the records to evaluate them for inclusion in the analysis. Subsequently, 2 reviewers independently screened the records on the basis of the abstract/full text. Disagreements on the inclusion of articles were resolved by consensus-based discussion. Articles were included when they fulfilled the following criteria: (1) women with cervical cancer, (2) minimum of 20 patients with cervical cancers included, (3) treatment consisted of primary radiation therapy, including both EBRT and BT, and platinum-based chemotherapy, (4) the relationship between predictive factors and GI, vaginal, or GU toxicity or insufficiency fractures was quantified, and (5) the article was published after 2005 and an English full-text was available. Records comprising reviews, editorials, guidelines, opinions, letters, and conference abstracts were excluded. This review was not registered.

### Quality assessment

The Cochrane Methods Prognosis group recommends the Quality In Prognosis Studies (QUIPS) tool for assessing the

risk of bias in prognostic factor finding studies.<sup>28,29</sup> The focus of this tool is on the validity and bias in studies investigating prognostic factors and comprises 6 domains that can inform on the risk of bias. For each domain, the article is assigned a judgment of high, moderate, or low risk of bias. In this systematic review, 3 out of the 6 domains, namely outcome measurement, study confounding, and statistical analysis and reporting, were considered to be most relevant for evaluating the quality of the included articles. One reviewer used these 3 domains to initially assess all included articles in the first assessment round. Articles identified as having a high risk of bias, when at least 2 out of the 3 domains had a high risk of bias, were excluded from further judgment and analysis. Articles identified as having a low or moderate risk of bias were evaluated by the same reviewer for the remaining 3 domains in the second assessment round: study participation, study attrition, and prognostic factor measurement. Judgments were discussed with a second reviewer. The sum of the ratings of the 6 domains determined the final judgment.

## Data extraction and analysis

One reviewer collected data from the articles, which included the source of data, patient enrollment period and number of patients enrolled, chemotherapeutic regimen, scoring system used for endpoint measurements, timepoints of measuring endpoints, modeling method, and characteristics of evaluated predictive factors. Because this systematic review focuses on GI, GU, and vaginal toxicity together with insufficiency fractures, solely predictive factors evaluating these endpoints were collected. Predictive factors were divided into dose-volume parameters and patient or treatment characteristics. Dose-volume parameters were categorized based on the corresponding organs at risk and dose reporting method. Dose was reported as the equivalent dose in 2 Gy fractions (EQD2). The normalized dose considered EBRT only (EQD2 EBRT), BT only (EQD2 BT), and EBRT and BT combined by adding the prescribed EBRT dose to the BT spatial dose (EQD2), which makes it a BT-related dose-volume parameter, or both techniques combined by adding the EBRT spatial dose to the BT spatial dose (EQD2 EBRT + BT). Treatment characteristics were evaluated per treatment modality. Consequently, predictive factors, corresponding endpoints, and statistical analysis method used for relationship quantification were organized in tables. When available, hazard ratios (HR) or odds ratios (OR) and corresponding 95% confidence intervals (CIs) from multivariable analyses evaluating candidate predictors from dose-volume parameters and patient or treatment characteristics were collected to visualize in figures. If articles reported a dosimetric threshold for toxicity prediction, these cut-off values were included in the figures as well. The majority of the cut-off values represent statistically optimized dosimetric thresholds that are most predictive of the treatment-related morbidity. Lastly, when studies assessed predictive factors for multiple endpoints, the clinically most

relevant endpoints were selected for visualization, as indicated in the figure descriptions.

## Results

### Eligible studies and quality assessment


Figure 1 visualizes the study flow diagram of the article screening process. Seventy-three studies were included in this systematic review and classified for risk of bias using the 3 domains of the QUIPS tool considered most important in the first assessment round. After this assessment, 47 of the 73 studies were rated as having a high risk of bias and therefore excluded from analysis. Consequently, 26 studies were evaluated in the second assessment round, of which 22 were finally classified as having a moderate risk of bias and 4 as having a low risk of bias. The QUIPS assessment is provided in Table EA (Supplementary Materials). Table 1 provides an overview of the included studies. Fifteen articles evaluated prospectively collected data and the median number of patients included for analysis was 227 (range, 40-1,860). Nineteen articles focused on late toxicity and, respectively, 14, 20, and 1 article(s) included GI toxicity, GU or vaginal toxicity, and insufficiency fractures as endpoint.

### GI toxicity

#### Dose-volume parameters

Out of the 14 studies evaluating GI toxicity, 9 studies reported on the correlation between dose-volume parameters and toxicity. Table EB (Supplementary Materials) provides an overview of the dose-volume parameters having a significant and those having a nonsignificant relationship with GI toxicity. The HR or OR of dose-volume parameters that were analyzed in multivariable analyses are indicated with “†” in Table EB (Supplementary Materials) and are shown in Figure 2. Figure 2 includes HR or OR per 10 Gy increase for continuous dose-volume parameters and per category for categorized dose-volume parameters.

Multiple studies demonstrated that BT-related parameters  $D_x \text{ cm}^3$ , representing the minimum doses of the most exposed small volumes, were related to late rectal toxicities or diarrhea. These included the rectum and the bowel EQD2  $D_2 \text{ cm}^3$ , having HR with relatively small 95% CIs, and the rectal wall EQD2  $D_2 \text{ cm}^3$  (>70 Gy) and rectosigmoid EQD2  $D_5 \text{ cm}^3$  (>65 Gy), having wide 95% CIs around the OR. In contrast, the EQD2  $D_2 \text{ cm}^3$  of the sigmoid colon alone was not significantly correlated with late GI toxicity (no HR or OR was reported). Significant correlations were found between EQD2 rectovaginal International Commission for Radiation Units and Measurements point (DICRU) and mean rectal biologically equivalent dose (BED) ( $\geq 110$  Gy) and late GI toxicity. The rectal BED was calculated by adding the BED of EBRT and BT using the linear quadratic formula.<sup>34</sup> Only 3 studies evaluated intermediate dose-



**Fig. 1.** Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram summarizing the article screening process.<sup>30</sup>

volume parameters of the GI tract.<sup>33,35,36</sup> Seppenwoolde et al<sup>35</sup> and Lee et al<sup>36</sup> retracted VxGy parameters from EBRT plans, whereas Ujaimi et al<sup>33</sup> calculated rectal EQD2 VxGy by obtaining the absolute volume of the rectum that received the difference between x Gy and the EBRT dose. The rectal EQD2 EBRT V30 Gy (>96%), bowel EQD2 EBRT V40 Gy, and rectal EQD2 EBRT V40 Gy were frequently reported as predictors of acute toxicity, whereas the rectal wall EQD2 V55 Gy (>11 cm<sup>3</sup>) was associated with late rectal toxicity. Lastly, the body absolute EQD2 EBRT V43 Gy and absolute EQD2 EBRT V57 Gy (when  $\geq 165$  cm<sup>3</sup> from a 60 Gy lymph node boost) were often identified as predictors of late GI toxicity. Parametrial dose and planning target volume were not associated with late GI toxicity.

### Patient and treatment characteristics

Table EC (Supplementary Materials) demonstrates the evaluated relationships between patient or treatment characteristics and GI toxicity. Available HR or OR from multivariable analyses are indicated with “†” in Table EC (Supplementary Materials) and visualized in Figure 3. In contrast to nodal boosts and EBRT technique, prescribed EBRT dose predicted some late GI toxicity endpoints. Studies disagreed on the relationship between para-aortic irradiation and late GI toxicity. Regarding BT, the total reference air kerma at 1-m distance (>2 cGy) and mean rectal geometric sparing factor (>0.7), which represents the ratio between the ICRU rectovaginal point dose and point A dose, were predictive of late GI toxicity. However, other

**Table 1 Overview of the included articles**

Reference first author	Source of data	Period of enrollment	No. of patients	Chemotherapy (no. patients, %)	Measured endpoint	Timing	Statistical analysis method	Predictive factors with respect to dose	Other predictive factors
Abbas <sup>62</sup>	Prospective	UK	227	Cisplatin (227, 100%)	RTOG GI, GU, skin	Acute	Logistic regression MVA	NA	GST polymorphisms
Beller <sup>63</sup>	Retrospective	1998- 2012	126	Cisplatin 40 mg/m <sup>2</sup> (102, 90.3%)	Urologic complications (Clavien-Dindo grade 3+)	After radiation therapy treatment	Logistic regression MVA	NA	Patient/treatment characteristics
Bockel <sup>64</sup>	Retrospective	2004- 2016	227	Cisplatin (210, 81.4%) Carboplatin (31, 12%)	CTCAEv4 GI	Late	Log rank or Cox regression MVA	EQD2 small volume parameters	Patient/treatment characteristics
Chen <sup>34</sup>	Retrospective	1993- 2006	392	Cisplatin (143, 37%)	RTOG rectum, bladder	Late	Logistic regression MVA	EQD2 EBRT parametrial dose, EQD2 bladder and rectal dose	Patient/treatment characteristics
Chen <sup>65</sup>	Retrospective	2001- 2007	212	Cisplatin (184, 86.8%)	RTOG rectum, bladder, and NRRIII	Late	Logistic regression MVA	EQD2 EBRT parametrial dose, EQD2 bladder and rectal dose (MVA)	Patient/treatment characteristics (group comparison)
Dankulchai <sup>66</sup>	Retrospective	UK	97	Cisplatin 40 mg/m <sup>2</sup> (62%, 60) or weekly carboplatin (33%, 32)	CTCAEv4 vaginal stricture	Late	Probit regression MVA*	EQD2 small volume parameters and point doses	Patient/treatment characteristics
Fokdal <sup>67</sup>	Prospective/ retrospective	1998- 2015	1,860	Cisplatin 40 mg/m <sup>2</sup> (1,654, 88.9%)	CTCAEv3 ureteral strictures	Late	Cox regression MVA	EQD2 small volume parameter (MVA)	Patient/ treatment characteristics (MVA)
Georg <sup>68</sup>	Retrospective	1998- 2003	141	Cisplatin 40 mg/m <sup>2</sup> (82, 58%)	LENT-SOMA rectum, sigmoid, bladder	Late	Group comparison and MVA	EQD2 small volume parameters and point dose (group comparison)	Patient / treatment characteristics (MVA)

(Continued)

**Table 1** (Continued)

Reference first author	Source of data	Period of enrollment	No. of patients	Chemotherapy (no. patients, %)	Measured endpoint	Timing	Statistical analysis method	Predictive factors with respect to dose	Other predictive factors
Ishikawa <sup>41</sup>	Retrospective	2011- 2013	42	Cisplatin or cisplatin with paclitaxel (29, 69%)	Fractures in L4/L5 or pelvic bones	Post treatment	Cox regression MVA	EQD2 EBRT + BT VxGy, D2 cc, and Dmean	Patient characteristics
Jensen <sup>31</sup>	Prospective	2008- 2015	900	Cisplatin (92%)	CTCAEv3 diarrhea or EORTC QLQ-C30 (both with LAPERS)	Late	Cox regression or binary logistic regression MVA	EQD2 small-dose volume parameter, point dose, and V60 Gy	Patient/treatment characteristics
Kim <sup>69</sup>	Prospective	2004- 2006	77	Cisplatin (66, 85.7%) Cisplatin + 5-FU (1, 1.3%)	RTOG rectum and sigmoid and RMC/LRC scores	Late	Stepwise logistic MVA	EQD2 small-dose parameters and point doses	Patient/treatment characteristics
Kirchheiner <sup>70</sup>	Prospective	2008- 2015	630	Cisplatin (UK)	CTCAEv3 vaginal stenosis	Late	Cox proportional hazard MVA	EQD2 point dose	Patient/treatment characteristics
Lee <sup>36</sup>	Retrospective	2004- 2015	245	Cisplatin (208, 84.9%)	CTCAEv3 GI	Acute and late	Cox proportional hazard MVA	EQD2 EBRT VxGy	Patient/treatment characteristics
Manea <sup>71</sup>	Retrospective	2004-2015	297	Cisplatin (278, 93.6%)	CTCAEv4 urinary	Late	MVA	EQD2 small-dose volume parameter, D50%, and point dose	Patient/treatment characteristics
Naik <sup>72</sup>	Prospective	2014- 2015	40	Cisplatin (40, 100%)	CTCAEv4 GI, GU	Acute	Group comparison with randomized groups	NA	Treatment characteristics
Pathy <sup>73</sup>	Prospective	2009- 2012	50	Cisplatin 40 mg/m <sup>2</sup> or 20 mg/m <sup>2</sup> (25 vs 25, 100% in total)	CTCAEv4 GI, GU	Acute	Group comparison with randomized groups	NA	Treatment characteristics

(Continued)

**Table 1** (Continued)

Reference first author	Source of data	Period of enrollment	No. of patients	Chemotherapy (no. patients, %)	Measured endpoint	Timing	Statistical analysis method	Predictive factors with respect to dose	Other predictive factors
Rodriguez-Lopez <sup>74</sup>	Retrospective	2007- 2017	242	Cisplatin (UK)	CTCAEv4 ureteral stenosis	Late	Logistic regression MVA	EQD2 small-dose volume parameter and CTV-D90	Patient/treatment characteristics
Ruanla <sup>39</sup>	Retrospective	2015- 2020	54	Cisplatin 40 mg/m <sup>2</sup> (48, 88.9%)	Modified Dische score vagina mucosal reaction	Late	Logistic regression MVA	EQD2 small-dose volume parameters and point doses	Patient characteristics
Seppenwoolde <sup>35</sup>	Prospective	2014- 2018	48	Cisplatin (41, 92%) Capecitabine (3, 6.25%)	CTCAEv4 all toxicity, GI, GU PRO QoL-C30, and EORTC QLQ-CX24	Acute	LASSO followed by logistic regression MVA	EQD2 EBRT VxGy	Patient/treatment characteristics
Sharma <sup>75</sup>	Prospective	2018- 2019	54	Cisplatin 35 mg/m <sup>2</sup> (UK)	CTCAEv4 GU, GI	Acute	Group comparison with randomized groups	NA	Treatment characteristic
Spampinato <sup>37</sup>	Prospective	2008- 2015	1,153 for CTCAE, 884 for EORTC analysis	Cisplatin (98%) Other (2%)	CTCAEv3 bladder fistula, bleeding, cystitis, EORTC-CX24 “pain during urinating” and “difficulty emptying bladder”	Late	Cox regression MVA	EQD2 small-dose volume parameter and point dose	Patient/treatment characteristics
Spampinato <sup>38</sup>	Prospective	2008- 2015	1,153 for CTCAE, 884 for EORTC analysis	Cisplatin (98%) Other (2%)	CTCAEv3 urinary frequency, urgency, incontinence, EORTC-CX24 “pass urine frequently” and “leaking” (both including LAPERS)	Late	Cox regression MVA	EQD2 small-dose volume parameter and point dose	Patient/treatment characteristics

(Continued)


**Table 1** (Continued)

Reference first author	Source of data	Period of enrollment	No. of patients	Chemotherapy (no. patients, %)	Measured endpoint	Timing	Statistical analysis method	Predictive factors with respect to dose	Other predictive factors
Spampinato <sup>32</sup>	Prospective	2008- 2015	1,199 for CTCAE, 1002 for EORTC analysis	Cisplatin (1,170 in CTCAE group, 97.6%)	CTCAEv3 GI, flatulence, fecal incontinence, proctitis, and anal/rectal bleeding, EORTC-C30 and CX24 constipation, abdominal cramps, difficulty in bowel control, and blood in stools (both including LAPERS)	Late	Cox regression MVA	EQD2 small-dose volume parameters and point dose	Patient/treatment characteristics
Ujaimi <sup>33</sup>	Prospective/ retrospective	2008- 2013	106	Cisplatin 40 mg/m <sup>2</sup> (82, 76%; others ≤4 cycles)	CTCAEv4 bladder, rectum (no diarrhea)	Late	Logistic regression MVA and group comparison	EQD2 VxGy and small-dose volume parameter	Patient/treatment characteristics
Wang <sup>76</sup>	Prospective	2016- 2018	351	Cisplatin 25 mg/m <sup>2</sup> or cisplatin 25 mg/m <sup>2</sup> combined with paclitaxel 135 mg/m <sup>2</sup> (UK)	CTCAEv3 vaginal stenosis	Late	Group comparison and Cox regression MVA	EQD2 point doses	Patient/treatment characteristics
Westerveld <sup>40</sup>	Prospective	2008- 2015	301	Cisplatin 40 mg/m <sup>2</sup> (97%)	CTCAEv3 vaginal stenosis	Late	Cox regression MVA	EQD2 EBRT, EQD2 BT and EQD2 EBRT + BT dose points	Patient/treatment characteristics

*Abbreviations:* 5-FU = fluorouracil; BT = brachytherapy; CTCAE = Common Terminology Criteria for Adverse Events; CTV = clinical target volume; EBRT = external beam radiation therapy; EORTC QLQ = European Organization for Research and Treatment of Cancer Quality of Life Questionnaire; EQD2 = equivalent dose in 2 Gy fractions; GI = gastrointestinal; GST = glutathione S-transferases; GU = genitourinary; L = lumbar vertebra; LAPERS = Late Substantial Patient-Reported Symptoms; LASSO = least absolute shrinkage and selection operator; LENT-SOMA = Late Effects Normal Tissue-Subjective, Objective, Management, Analytical; LRC = late rectal complication; MVA = multivariate analysis; NA = not applicable; NRRIII = nonrectal radiation-induced gastrointestinal injury; PRO = patient-reported outcome, QoL = quality of life; RMC = rectosigmoid mucosal change; RTOG = Radiation Therapy Oncology Group; UK = unknown; VxGy = volume of organ [%] receiving ≥ x Gy.

\* Dankulchai et al<sup>66</sup> also compared grade 1 to 3 vaginal stenosis groups, but these analyses were not included in their article.






**Fig. 2.** Odds and hazard ratios of dose-volume parameters, including 95% CIs if available, that were evaluated as predictive factors for late gastrointestinal toxicity. All ratios in the figure result from multivariable analyses performed in the analyzed studies. The studies by Jensen et al<sup>31</sup> and Spampinato et al<sup>32</sup> assessed multiple endpoints per predictive factor. From these studies, only ratios with respect to Common Terminology Criteria for Adverse Events grade 2+ and European Organization for Research and Treatment of Cancer Late Substantial Patient-Reported Symptoms<sup>31</sup> or Common Terminology Criteria for Adverse Events grade 2+ and European Organization for Research and Treatment of Cancer “quite a bit +”<sup>32</sup> were included in this figure. EQD2  $V_{55 Gy}$  was defined by Ujaimi et al<sup>33</sup> as the absolute volume of the rectum that received the difference between 55 Gy and the EBRT dose. The rectal biologically equivalent dose was calculated by adding the biologically equivalent dose of EBRT and BT using the linear quadratic formula.<sup>34</sup>

DICRU = International Commission for Radiation Units and Measurements point;  $Dx cm^3$  = dose [Gy] received by volume  $x cm^3$ ; EQD2 = EBRT and BT combined by adding the prescribed EBRT dose to the BT spatial dose reported as EQD2; EQD2 EBRT = only external beam radiation therapy dose reported as EQD2;  $VxGy$  = volume of organ [%] receiving  $\geq x Gy$ . \*Ratio falls outside the figure. *Abbreviations:* BT = brachytherapy; EBRT = external beam radiation therapy; EQD2 = equivalent dose in 2 Gy fractions; LN = lymph node.

brachytherapy parameters, including the size of residual vaginal tumor at first BT, dose rate, and applicator characteristics, did not influence toxicity. Similarly, studies disagreed on the effect of chemotherapy on acute and late GI toxicity. With respect to patient characteristics, the influence of underweight, overweight, age, stage, rectal invasion, and diabetes mellitus on GI toxicity had inconsistent results across studies. Baseline symptoms, grade 2 to 4 bladder

complications after treatment, smoking, and specific genetic polymorphisms of glutathione S-transferase genotype, which ameliorate toxic reactive oxygen species created by chemoradiotherapy, were significantly correlated with acute or late GI toxicity, but corresponding HR or OR showed wide 95% CIs. Lastly, tumor size, histology, chronic diseases, previous major surgery, pelvic lymph node status, hypertension, and alcohol were not predictive of toxicities.



**Fig. 3.** Odds and hazard ratios, including 95% CIs if available, of patient and treatment characteristics that were evaluated as predictive factors for gastrointestinal toxicity. On the right Y-axis, subcategories of predictive factors are defined. All ratios in the figure result from multivariable analyses performed in the analyzed studies. The studies by Jensen et al<sup>31</sup> and Spampinato et al<sup>32</sup> assessed multiple endpoints per predictive factor. From these studies, only ratios with respect to Common Terminology Criteria for Adverse Events grade 2+ and European Organization for Research and Treatment of Cancer Late Substantial Patient-Reported Symptoms<sup>31</sup> or Common Terminology Criteria for Adverse Events grade 2+ and European Organization for Research and Treatment of Cancer “quite a bit +”<sup>32</sup> were included in this figure.

*Abbreviations:* BMI = body mass index; EBRT = external beam radiation therapy; GST = glutathione S-transferase; PAO = para-aortic; RGFS = mean rectal geometric sparing factor; TRAK = total reference air kerma.


## GU and vaginal toxicity

### Dose-volume parameters

Out of the 20 studies evaluating candidate predictors of GU and vaginal toxicities, 15 assessed dose-volume parameters, which are outlined in [Table ED \(Supplementary Materials\)](#). Available HR or OR are indicated with “†” and are shown in [Figure 4](#). [Figure 4](#) includes HR or OR per 10 Gy increase for continuous dose-volume parameters and per category for categorized dose-volume parameters.

BT-related dose-volume parameters from the bladder, including EQD2 D0.1 cm<sup>3</sup> and EQD2 D2 cm<sup>3</sup>, were predictive of some late bladder toxicity endpoints. Inconsistent

results were reported on the correlation between EQD2 EBRT + BT posterior-inferior border of symphysis (+2 cm and -2 cm) and EQD2 bladder DICRU and late urinary or vaginal toxicity, whereas the bladder BED ( $\geq 100$  Gy) and the EQD2 rectovaginal DICRU were predictive of late urinary or vaginal toxicity. The bladder BED was calculated by adding the BED of EBRT and BT using the linear quadratic formula.<sup>34</sup> Additionally, the mean dose of the left and right lateral vaginal points in 5-mm depth (VLat5 mmMeanLR; continuous or >95 Gy) was associated with late vaginal stenosis grade 2+. Evaluation of volume-based parameters of each separate part of the vagina did not show associations with toxicity.<sup>39</sup> Bladder EQD2 EBRT V40 Gy was the only intermediate dose parameter assessed, and it contributed to




**Fig. 4.** Odds and hazard ratios including 95% CIs of dose-volume parameters, and cut-off values if reported, that were evaluated as predictive factors for late genitourinary and vaginal toxicity. All ratios in the figure result from multivariable analyses performed in the analyzed studies. The studies by Spampinato et al<sup>37,38</sup> assessed multiple endpoints per predictive factor. From these studies, only ratios with respect to Common Terminology Criteria for Adverse Events grade 2+ and European Organization for Research and Treatment of Cancer “quite a bit +” were included in this figure. The bladder biologically equivalent dose was calculated by adding the biologically equivalent dose of EBRT and BT using the linear-quadratic formula.<sup>34</sup> \*Ratio falls outside the figure. *Abbreviations:* BT = brachytherapy; DICRU = International Commission for Radiation Units and Measurements point;  $D_x cm^3$  = dose [Gy] received by volume  $\times cm^3$ ; EBRT = external beam radiation therapy; EQD2 = equivalent dose in 2 Gy fractions; PIBS = posterior-inferior borders of pubic symphysis; VLat5 mmMeanLR = mean dose of the left and right lateral vaginal points in 5-mm depth.

acute low-grade bladder toxicities. The effect of the bladder wall, bladder trigone, ureter, clinical target volume-HR, or body dose was only evaluated in univariable analyses. Lastly, parametrial dose did not predict late bladder toxicity.

#### Patient and treatment characteristics

Table EE (Supplementary Materials) comprises the evaluated relationships between patient or treatment characteristics and GU or vaginal toxicities. Available HR or OR are indicated with “†” and are shown in Figure 5. Dose from EBRT only and EBRT and BT together, EBRT technique, and EBRT boosts were not predictive of GU or vaginal toxicity.

Studies found associations between the mean bladder geometric sparing factor (>0.9) and a shorter vaginal reference length and late GU or vaginal toxicity. Studies reported inconsistent results on the effect of BT technique (intracavitary vs a combination of intracavitary and interstitial) and applicator. Other BT parameters, including dose (rate), ovoid size, and residual vaginal tumor at BT, were not associated with late GU or vaginal toxicity. One study demonstrated a significant correlation between chemotherapy and late bladder complications with wide 95% CIs for the corresponding HR, but many other studies reported no significant associations between chemotherapy characteristics and GU or



**Fig. 5.** Odds and hazard ratios including 95% CIs of patient and treatment characteristics that were evaluated as predictive factors for genitourinary and vaginal toxicity. On the right Y-axis, subcategories of predictive factors are defined. All ratios in the figure result from multivariable analyses performed in the analyzed studies. The studies by Spampinato et al.<sup>37,38</sup> assessed multiple endpoints per predictor. From these studies, Common Terminology Criteria for Adverse Events grade 2+ and European Organization for Research and Treatment of Cancer “quite a bit +” were included in this figure. For Westerveld et al.,<sup>40</sup> the weighted hazard ratio for the factors age and vaginal involvement was calculated and included in the figure. *Abbreviations:* BGSF = mean bladder geometric sparing factor; BMI = body mass index; BT = brachytherapy; EBRT = external beam radiation therapy.

vaginal toxicity. Lastly, for patient characteristics, baseline symptoms and extent of vaginal involvement at time of diagnosis were predictors of late GU or vaginal toxicity. Obesity was significantly associated with multiple endpoints, while underweight and overweight were not. Pre-existing hydronephrosis and grade 2+ rectal complications were also significantly associated with GU toxicity but showed wide 95% CIs. Studies disagreed on the influence of smoking, age, and alcohol. No studies found stage predictive of GU toxicity.

### Insufficiency fractures

Only 1 of the included articles in this systematic review evaluated posttreatment insufficiency fractures.<sup>41</sup> Univariable

analysis showed that fractures were more frequently identified in patients with advanced age, a low body mass index, no use of concomitant chemotherapy, and postmenopausal status. Additionally, pretreatment computed tomography (CT) densities were significantly lower among patients with fractures, except at the ilium and the ischium, which may reflect osteoporosis. Lastly, fractures of the pubis were more commonly observed for higher V30 Gy (>75%), V40 Gy (>55%), and V50 Gy (>25%) of the pubic bones. For the multivariable analysis, CT densities and the dose-volume histogram parameters for pubic fractures were included, as the patient characteristics were correlated with CT densities. Only the CT densities were then found significant for pubic bone fractures.

## Discussion

In this systematic review, predictive factors for GI, GU, and vaginal toxicities, and insufficiency fractures after primary chemoradiation with adaptive image-guided BT for LACC were evaluated. The majority of the analyzed studies focused on BT-related dose-volume parameters. BT-related dose-volume parameters of the GI tract were mainly predictive of late GI toxicities, most notably the EQD2 D2 cm<sup>3</sup> of the rectum and bowel, differing from parameters of the GU tract and GU toxicity. Point doses, including EQD2 rectovaginal DICRU and VLat5 mmMeanLR (continuous or >95 Gy), contributed to late GI and vaginal toxicities. In contrast, a limited number of studies investigated intermediate dose-volume parameters with a large EBRT dose contribution. These studies found that the rectal EQD2 EBRT V30 Gy (>96%), bowel EQD2 EBRT V40 Gy, rectal EQD2 EBRT V40 Gy, and bladder EQD2 EBRT V40 Gy were frequently reported as predictors of acute GI or GU toxicity. Rectal EQD2 V55 Gy (>11 cm<sup>3</sup>) was associated with late rectal toxicity. Lastly, a large volume of the body absolute EQD2 EBRT V57 Gy ( $\geq 165$  cm<sup>3</sup>) when boosting lymph nodes and body absolute EQD2 EBRT V43 Gy predicted multiple GI toxicities. Furthermore, total reference air kerma at 1-m distance (>2 cGy) and vaginal reference length contributed to, respectively, late GI toxicity and vaginal stenosis. Studies disagreed on the relationship between chemotherapy and toxicities. Relationships between patient characteristics and GI toxicity had wide 95% CIs or were inconsistent, but baseline symptoms, obesity, and extent of vaginal involvement at diagnosis were mostly associated with GU toxicity or vaginal stenosis. Only 1 study evaluated insufficiency fractures and demonstrated that pretreatment CT densities, which may reflect osteoporosis, were predictive of this type of toxicity.

A restricted number of studies evaluated dose-volume parameters that were, to a large extent, determined by EBRT spatial dose. However, they detected multiple intermediate dose-volume parameters to be associated with toxicities. Numerous studies examined EBRT-related dose-volume parameters for treatment-related toxicity in other pelvic cancers. For GI toxicity, a systematic review by Holyoake et al<sup>42</sup> showed a significant relationship between the small bowel V5 Gy, V10 Gy, V30 Gy, V45 Gy and acute grade 3+ toxicity in patients with rectal cancer treated with chemoradiation. Studies evaluating treatment-related toxicity in patients with anal cancer treated with chemoradiotherapy reported intermediate dose-volume parameters of the bowel as predictors of late GI toxicity, including large bowel loops V20 Gy<sup>43</sup> or small bowel loops V30 Gy,<sup>43</sup> or acute GI toxicity, including bowel cavity V30 Gy<sup>44,43</sup> or small bowel loops V35 Gy.<sup>45</sup> For GU or vaginal toxicity, studies on anal cancer reported worse urinary function for higher bladder V40 Gy,<sup>43,46</sup> and studies on both rectal and anal cancer suggested a vaginal Dmean <43 Gy to reduce the risk of severe vaginal stenosis.<sup>47</sup> These studies indicate that the EBRT spatial dose is associated with GI, GU, or vaginal toxicities. Notably, the EMBRACE-group discussed

dose planning aims for LACC and advocated for further analysis and reporting of low and intermediate dose levels (15-60 Gy) to give insights into morbidity development.<sup>48</sup> As summing BT and EBRT spatial dose is currently challenging, the EMBRACE group recommends to report EBRT dose-volume parameters to reflect these dose levels. EBRT-related dose-volume parameters should be included in NTCP models and could be improved with advanced radiation therapy techniques such as proton therapy.

Only 1 of the included studies evaluated predictive factors for insufficiency fractures despite the relatively high incidence reported in literature and the associated morbidity. An explanation could be that the incidence of insufficiency fractures in clinical practice is underestimated, because 40% of the insufficiency fractures are asymptomatic and might therefore remain undetected in the current follow-up routine. However, these cases could become symptomatic and affect the quality of life.<sup>6</sup> Other studies that were identified with the literature search did not fulfill the inclusion criteria or were rated as a high risk of bias. Three recent systematic reviews or meta-analyses evaluating insufficiency fractures in women treated for gynecologic malignancies demonstrated significant associations between older age,<sup>4</sup> EBRT technique,<sup>6</sup> osteoporosis,<sup>5</sup> postmenopausal state,<sup>5</sup> or a history of diabetes mellitus<sup>5</sup> and the incidence of insufficiency fractures. These predictors might be applicable for the patient group evaluated in this systematic review as well. As both the incidence and survival of LACC have increased, insufficiency fractures have become a more clinically relevant late toxicity. Additionally, interest in bone-sparing radiation therapy has increased because studies reported dose-volume parameters to be associated with insufficiency fractures, including sacrum D50%<sup>49,50</sup> and V40 Gy.<sup>51</sup> Future clinical trials could further evaluate risk factors for insufficiency fractures and explore the potential and clinical benefits of bone sparing radiation therapy for insufficiency fractures in patients with pelvic cancer.

A recent study by Suvaal et al<sup>52</sup> reported that half of the sexually active women treated with primary chemoradiation for LACC reported vaginal functioning problems and sexual distress, while the majority of the women had no or only mild physician-reported vaginal changes over time. The studies about vaginal morbidity that were analyzed in our review mainly focused on physician-assessed grading using Common Terminology Criteria for Adverse Events or Radiation Therapy Oncology Group, but patient-reported endpoints might be more relevant for quality of life.

The studies analyzed in this systematic review did not agree on the associations between patient or treatment characteristics and GI toxicity, but agreed upon the effect of baseline symptoms, tumor extension into the vagina, and obesity on GU or vaginal toxicities. Reviews on other pelvic cancers treated with radiation therapy suggested that older age,<sup>44,53</sup> smoking,<sup>44</sup> the addition of EBRT to BT,<sup>53</sup> higher tumor stage,<sup>53</sup> and baseline bladder complications<sup>53</sup> were linked to GI toxicity, and poor baseline GU function,<sup>54</sup> older age,<sup>54</sup> presence of diabetes,<sup>54</sup> and smoking<sup>54</sup> were linked to GU toxicity.

The lack of clinically applicable NTCP models for toxicities in women with primary LACC treated with platinum-based chemoradiotherapy and BT was the rationale for this systematic review. The majority of the identified studies pre-selected variables based on univariable analysis to subsequently include these in a multivariable analysis. Full prediction models that allow for predictions of individual patients were not reported. Ideally, studies provide full equations, including regression coefficients and model intercept, and information on model performance to facilitate interpretation and clinical implementation.<sup>26,55,56</sup>

To build a high-quality and reliable NTCP model, relevant candidate predictors and endpoints could be identified based on clinical reasoning and literature.<sup>26</sup> However, almost half of the studies included in this systematic review were assigned a judgment of high risk of bias and removed for analysis. Potential biases in the domains of outcome measurement, study confounding, and statistical analysis could result in reporting invalid associations between the prognostic factor and the endpoints.<sup>28</sup> First, the variety of outcome measurement methods to classify normal tissue complications make endpoint comparison difficult. As the Quantitative Analysis of Normal Tissue Effects in the Clinic (QUANTEC) papers pointed out, there is a large variety in endpoint definitions because of different timepoints, grouping of scored toxicities into grades or organ systems, and different grading systems used.<sup>57</sup> Besides, 11 out of the 26 included studies had a retrospective design. These studies relied on toxicity data collected from patient records, which is often not reported in a standardized manner and therefore may lead to a variation in toxicity registration within and between studies. Ideally, centers and cooperative groups would use 1 standardized scoring system for outcome variables. Additionally, various methods to report EBRT and BT dose were used, which complicates comparison among studies. The majority of the included studies followed the recommendations of the Gynaecological Groupe Européen de Curiethérapie and the European Society for Radiotherapy & Oncology (GYN GEC-ESTRO) Working Group by presuming a homogeneous EBRT dose and an inhomogeneous BT dose that was spatially identical for each BT fraction.<sup>58</sup> However, other studies considered that toxicities might be dose-spatial dependent and included information on the spatial nature of the dose distribution.<sup>59</sup> Second, regarding bias owing to study confounding, multicollinearity between predictors was not always reported. As a result, the quantified relationship between selected predictors and endpoints might be less robust.<sup>26,55</sup> Lastly, the rule of thumb for applying logistic models is that a minimum of 10 events per candidate predictor should be used. Even though the validity of this rule has been questioned,<sup>60</sup> studies with a relatively low toxicity event rate or a low number of evaluated patients showed large 95% CIs for HR or OR in this systematic review.

The vast majority of the reported dosimetric cut-off values were determined by optimizing their discriminant ability for toxicities. Dosimetric cut-off values are easy to comprehend and to use during treatment optimization and

are therefore often reported. However, a statistically optimal cut-off value might underestimate variability within the 2 groups and overestimate the influence of the variable on the outcome.<sup>61</sup> Preferably, dose-volume parameters are kept continuous and their relationship with toxicities is represented in regression models.

This systematic review was the first review to provide a comprehensive overview of predictors of GI, GU, or vaginal toxicity and insufficiency fractures for primary LACC treated with chemoradiotherapy, including EBRT, platinum-based chemotherapy, and BT. BT-related dose-volume parameters of the GI tract were demonstrated to be predictive of GI toxicities, most notably the EQD2 D2 cm<sup>3</sup> of the rectum and bowel, in contrast to GU parameters and toxicity. Point doses, including EQD2 rectovaginal DICRU and VLat5 mmMeanLR, were related to late toxicities. Only a limited number of studies analyzed intermediate dose-volume parameters with a large EBRT dose contribution, but the rectum EQD2 EBRT V30 Gy, V40 Gy, and V55 Gy, bowel and bladder EQD2 EBRT V40 Gy were reported as predictive of GI or GU toxicities. Large body volumes receiving 57 Gy from 60 Gy lymph node boosts and body absolute EQD2 EBRT V43 Gy were often identified as predictors of GI toxicities. Mainly BT-related treatment characteristics were correlated with toxicities, whereas studies disagreed on the influence of chemotherapy. Patient characteristics, including tumor extension in the vagina at time of diagnosis, baseline symptoms, and obesity, were associated with GU or vaginal toxicity. Lastly, only 1 article evaluated risk factors for insufficiency fractures and found pretreatment bone densities assessed with CT to be predictive. Our systematic review identified and provided an overview of candidate predictors to include in NTCP models. However, more attention should be paid to insufficiency fractures. Further research is required to assess the relationship between dose-volume parameters from EBRT and toxicities. Lastly, larger studies evaluating factors associated with treatment-related toxicities in women with LACC are warranted to quantify the associations. Our findings contribute to NTCP model development and validation to facilitate shared decision making, treatment optimization, and the selection of the most beneficial radiation therapy technique, including proton therapy, to minimize toxicity risks in clinical practice.

## References

1. Cibula D, Pötter R, Planchamp F, et al. The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology guidelines for the management of patients with cervical cancer. *Virchows Archiv* 2018;472:919-936.
2. Vittrup AS, Kirchheiner K, Pötter R, et al. Overall severe morbidity after chemo-radiotherapy and MRI guided adaptive brachytherapy in locally advanced cervical cancer: Results from the EMBRACE-I study. *Int J Radiat Oncol Biol Phys* 2023;116:807-824.
3. Horeweg N, Creutzberg CL, Rijkman EC, et al. Efficacy and toxicity of chemoradiation with image-guided adaptive brachytherapy for locally advanced cervical cancer. *Int J Gynecol Cancer* 2019;29:257-265.

4. Chung YK, Lee Y-K, Yoon B-H, et al. Pelvic insufficiency fractures in cervical cancer after radiation therapy: A meta-analysis and review. *In Vivo* 2021;35:1109-1115.
5. Razavian N, Laucis A, Sun Y, et al. Radiation-induced insufficiency fractures after pelvic irradiation for gynecologic malignancies: A systematic review. *Int J Radiat Oncol Biol Phys* 2020;108:620-634.
6. Sapienza LG, Salcedo MP, Ning MS, et al. Pelvic insufficiency fractures after external beam radiation therapy for gynecologic cancers: A meta-analysis and meta-regression of 3929 patients. *Int J Radiat Oncol Biol Phys* 2020;106:475-484.
7. Pötter R, Tanderup K, Schmid MP, et al. MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): A multi-centre prospective cohort study. *Lancet Oncol* 2021;22:538-547.
8. Spampinato S, Tanderup K, Lindegaard JC, et al. Association of persistent morbidity after radiotherapy with quality of life in locally advanced cervical cancer survivors. *Radiother Oncol* 2023;181:109501.
9. Andreyev J. Gastrointestinal symptoms after pelvic radiotherapy: A new understanding to improve management of symptomatic patients. *Lancet Oncol* 2007;8:1007-1017.
10. Pan YB, Maeda Y, Wilson A, et al. Late gastrointestinal toxicity after radiotherapy for anal cancer: A systematic literature review. *Acta Oncol* 2018;57:1427-1437.
11. Sipaviciute A, Sileika E, Burneckis A, Dulskas A. Late gastrointestinal toxicity after radiotherapy for rectal cancer: A systematic review. *Int J Colorectal Dis* 2020;35:977-983.
12. Sauter C, Peeken JC, Borm K, et al. Quality of life in patients treated with radiochemotherapy for primary diagnosis of anal cancer. *Sci Rep* 2022;12:4416.
13. Mirabeau-Beale KL, Viswanathan AN. Quality of life (QOL) in women treated for gynecologic malignancies with radiation therapy: A literature review of patient - reported outcomes. *Gynecol Oncol* 2014;134:403-409.
14. Sims TT, Klopp AH. Intensified systemic therapy regimens in combination with definitive radiation for treatment of cervical cancer. *Semin Radiat Oncol* 2020;30:265-272.
15. Hymel R, Jones GC, Simone CB. Whole pelvic intensity-modulated radiotherapy for gynecological malignancies: A review of the literature. *Crit Rev Oncol Hematol* 2015;94:371-379.
16. Berger T, Seppenwoolde Y, Pötter R, et al. Importance of technique, target selection, contouring, dose prescription, and dose-planning in external beam radiation therapy for cervical cancer: Evolution of practice from EMBRACE-I to II. *Int J Radiat Oncol Biol Phys* 2019;104:885-894.
17. Ahmad R, Bondar L, Voet P, et al. A margin-of-the-day online adaptive intensity-modulated radiotherapy strategy for cervical cancer provides superior treatment accuracy compared to clinically recommended margins: A dosimetric evaluation. *Acta Oncol* 2013;52:1430-1436.
18. Sturdza A, Pötter R, Fokdal LU, et al. Image guided brachytherapy in locally advanced cervical cancer: Improved pelvic control and survival in RetroEMBRACE, a multicenter cohort study. *Radiother Oncol* 2016;120:428-433.
19. Lin Y, Chen K, Lu Z, et al. Intensity-modulated radiation therapy for definitive treatment of cervical cancer: A meta-analysis. *Radiat Oncol* 2018;13:177.
20. van de Sande MA, Creutzberg CL, van de Water S, et al. Which cervical and endometrial cancer patients will benefit most from intensity-modulated proton therapy? *Radiother Oncol* 2016;120:397-403.
21. Milby AB, Both S, Ingram M, Lin LL. Dosimetric comparison of combined intensity-modulated radiotherapy (IMRT) and proton therapy versus IMRT alone for pelvic and para-aortic radiotherapy in gynecologic malignancies. *Int J Radiat Oncol Biol Phys* 2012;82:e477-e484.
22. Gort EM, Beukema JC, Matysiak W, et al. Inter-fraction motion robustness and organ sparing potential of proton therapy for cervical cancer. *Radiother Oncol* 2021;154:194-200.
23. van de Schoot AJAJ, de Boer P, Crama KF, et al. Dosimetric advantages of proton therapy compared with photon therapy using an adaptive strategy in cervical cancer. *Acta Oncol* 2016;55:892-899.
24. Langendijk JA, Lambin P, De Ruyscher D, et al. Selection of patients for radiotherapy with protons aiming at reduction of side effects: The model-based approach. *Radiother Oncol* 2013;107:267-273.
25. Widder J, van der Schaaf A, Lambin P, et al. The quest for evidence for proton therapy: Model-based approach and precision medicine. *Int J Radiat Oncol Biol Phys* 2016;95:30-36.
26. Van den Bosch L, Schuit E, van der Laan HP, et al. Key challenges in normal tissue complication probability model development and validation: Towards a comprehensive strategy. *Radiother Oncol* 2020;148:151-156.
27. Palma G, Monti S, Conson M, et al. Normal tissue complication probability (NTCP) models for modern radiation therapy. *Semin Oncol* 2019;46:210-218.
28. Hayden JA, van der Windt DA, Cartwright JL, et al. Assessing bias in studies of prognostic factors. *Ann Int Med* 2013;158:280-286.
29. Cochrane Methods Prognosis. (n.d.). FAQ | *Cochrane Prognosis*. Retrieved April 13, 2023, from <https://methods.cochrane.org/prognosis/tools>.
30. Liberati M, Tetzlaff J, Altman D, et al. Preferred reporting items for systematic reviews and meta analyses: THE PRISMA statement. *PLoS Med* 2009;6:1-6.
31. Jensen NBK, Potter R, Spampinato S, et al. Dose-volume effects and risk factors for late diarrhea in cervix cancer patients after radiochemotherapy with image guided adaptive brachytherapy in the EMBRACE I study. *Int J Radiat Oncol Biol Phys* 2021;109:688-700.
32. Spampinato S, Jensen NBK, Potter R, et al. Severity and persistency of late gastrointestinal morbidity in locally advanced cervical cancer: Lessons learned from EMBRACE-I and implications for the future. *Int J Radiat Oncol Biol Phys* 2022;112:681-693.
33. Ujaimi R, Milosevic M, Fyles A, et al. Intermediate dose-volume parameters and the development of late rectal toxicity after MRI-guided brachytherapy for locally advanced cervix cancer. *Brachytherapy* 2017;16:968-975.e2.
34. Chen SW, Liang JA, Hung YC, et al. Geometrical sparing factors for the rectum and bladder in the prediction of grade 2 and higher complications after high-dose-rate brachytherapy for cervical cancer. *Int J Radiat Oncol Biol Phys* 2009;75:1335-1343.
35. Seppenwoolde Y, Majercakova K, Buschmann M, et al. Early morbidity and dose-volume effects in definitive radiochemotherapy for locally advanced cervical cancer: A prospective cohort study covering modern treatment techniques. *Strahlentherapie und Onkologie* 2021;197:505-519.
36. Lee J, Chang CL, Lin JB, et al. The effect of body mass index and weight change on late gastrointestinal toxicity in locally advanced cervical cancer treated with intensity-modulated radiotherapy. *Int J Gynecol Cancer* 2018;28:1377-1386.
37. Spampinato S, Fokdal LU, Potter R, et al. Risk factors and dose-effects for bladder fistula, bleeding and cystitis after radiotherapy with imaged-guided adaptive brachytherapy for cervical cancer: An EMBRACE analysis. *Radiother Oncol* 2021;158:312-320.
38. Spampinato S, Fokdal LU, Potter R, et al. Importance of the ICRU bladder point dose on incidence and persistence of urinary frequency and incontinence in locally advanced cervical cancer: An EMBRACE analysis. *Radiother Oncol* 2021;158:300-308.
39. Ruanla J, Muangwong P, Kittidachanan K, et al. The association of vagina equivalent dose in 2Gy fraction (EQD(2)) to late vagina toxicity in patients of cervical cancer treated with WPRT plus IGABT. *Brachytherapy* 2022;21:658-667.
40. Westerveld H, Kirchheiner K, Nout RA, et al. Dose-effect relationship between vaginal dose points and vaginal stenosis in cervical cancer: An EMBRACE-I sub-study. *Radiother Oncol* 2022;168:8-15.
41. Ishikawa K, Yamashiro T, Ariga T, et al. Predictive factors of posttreatment fracture by definitive radiotherapy for uterine cervical cancer. *Japan J Radiol* 2021;39:93-99.
42. Holyoake DLP, Partridge M, Hawkins MA. Systematic review and meta-analysis of small bowel dose-volume and acute toxicity in conventionally-fractionated rectal cancer radiotherapy. *Radiother Oncol* 2019;138:38-44.
43. De B, Corrigan KL, Rooney MK, et al. Patient-reported bowel and urinary function in long-term survivors of squamous cell carcinoma of

- the anus treated with definitive intensity modulated radiation therapy and concurrent chemotherapy. *Int J Radiat Oncol Biol Phys* 2022;114:78-88.
44. Nilsson MP, Gunnlaugsson A, Johnsson A, Scherman J. Dosimetric and clinical predictors for acute and late gastrointestinal toxicity following chemoradiotherapy of locally advanced anal cancer. *Clin Oncol* 2022;34:e35-e44.
  45. Lukovic J, Hosni A, Liu A, et al. Evaluation of dosimetric predictors of toxicity after IMRT with concurrent chemotherapy for anal cancer. *Radiother Oncol* 2023;178 109429.
  46. Koerber SA, Seither B, Slynko A, et al. Chemoradiation in female patients with anal cancer: Patient-reported outcome of acute and chronic side effects. *Tumori J* 2019;105:174-180.
  47. Son CH, Law E, Oh JH, et al. Dosimetric predictors of radiation-induced vaginal stenosis after pelvic radiation therapy for rectal and anal cancer. *Int J Radiat Oncol Biol Phys* 2015;92:548-554.
  48. Tanderup K, Nesvacil N, Kirchheiner K, et al. Evidence-based dose planning aims and dose prescription in image-guided brachytherapy combined with radiochemotherapy in locally advanced cervical cancer. *Semin Radiat Oncol* 2020;30:311-327.
  49. Ramlov A, Pedersen EM, Rohl L, et al. Risk factors for pelvic insufficiency fractures in locally advanced cervical cancer following intensity modulated radiation therapy. *Int J Radiat Oncol Biol Phys* 2017;97:1032-1039.
  50. Mori Y, Okonogi N, Matsumoto S, et al. Effects of dose and dose-averaged linear energy transfer on pelvic insufficiency fractures after carbon-ion radiotherapy for uterine carcinoma. *Radiother Oncol* 2022;177:33-39.
  51. Mir R, Dragan A, Mistry H, et al. Sacral insufficiency fracture following pelvic radiotherapy in gynaecological malignancies: Development of a predictive model. *Clin Oncol* 2021;33:e101-e109.
  52. Suvaal I, Kirchheiner K, Nout R, et al. Vaginal changes, sexual functioning and distress of women with locally advanced cervical cancer treated in the EMBRACE vaginal morbidity substudy. *Gynecol Oncol* 2023;170:123-132.
  53. Tohidinezhad F, Willems Y, Berbee M, et al. Prediction models for brachytherapy-induced rectal toxicity in patients with locally advanced pelvic cancers: A systematic review. *J Contemp Brachytherapy* 2022;14:411-422.
  54. Martin JM, Richardson M, Siva S, et al. Mechanisms, mitigation, and management of urinary toxicity from prostate radiotherapy. *Lancet Oncol* 2022;23:e534-e543.
  55. McDonald AM, Schneider CS, Stahl JM, et al. A focused review of statistical practices for relating radiation dose-volume exposure and toxicity. *Radiat Oncol* 2023;18:57.
  56. Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD) the TRIPOD statement. *Circulation* 2015;131:211-219.
  57. Jackson A, Marks LB, Bentzen SM, et al. The lessons of QUANTEC: Recommendations for reporting and gathering data on dose-volume dependencies of treatment outcome. *Int J Radiat Oncol Biol Phys* 2010;76:S155-S160.
  58. Pötter R, Haie-Meder C, Van Limbergen E, et al. Recommendations from gynaecological (GYN) GEC ESTRO working group (II): Concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy—3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology. *Radiother Oncol* 2006;78:67-77.
  59. Ebert MA, Gulliford S, Acosta O, et al. Spatial descriptions of radiotherapy dose: Normal tissue complication models and statistical associations. *Phys Med Biol* 2021;66 12TR01.
  60. Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic and Cox regression. *Am J Epidemiol* 2006;165:710-718.
  61. Altman DG, Royston P. The cost of dichotomising continuous variables. *BMJ* 2006;332:1080.
  62. Abbas M, Kushwaha VS, Srivastava K, et al. Impact of GSTM1, GSTT1 and GSTP1 genes polymorphisms on clinical toxicities and response to concomitant chemoradiotherapy in cervical cancer. *Br J Biomed Sci* 2018;75:169-174.
  63. Beller HL, Rapp DE, Zillioux J, et al. Urologic complications requiring intervention following high-dose pelvic radiation for cervical cancer. *Urology* 2021;151:107-112.
  64. Bockel S, Escande A, Dumas I, et al. Total reference air kerma is associated with late bowel morbidity in locally advanced cervical cancer patients treated with image-guided adaptive brachytherapy. *J Clin Med* 2019;8:21.
  65. Chen SW, Liang JA, Shiau AC, et al. Lack of the dose-rate effect of 192Ir source activity on pelvic control and late complications after high-dose-rate brachytherapy for cervical cancer. *J Radiat Res* 2010;51:173-179.
  66. Dankulchai P, Harn-Utaismee P, Prasartseree T, et al. Vaginal 11-point and volumetric dose related to late vaginal complications in patients with cervical cancer treated with external beam radiotherapy and image-guided adaptive brachytherapy. *Radiother Oncol* 2022;174:77-86.
  67. Fokdal L, Tanderup K, Potter R, et al. Risk factors for ureteral stricture after radiochemotherapy including image guided adaptive brachytherapy in cervical cancer: Results from the EMBRACE studies. *Int J Radiat Oncol Biol Phys* 2019;103:887-894.
  68. Georg P, Lang S, Dimopoulos JC, et al. Dose-volume histogram parameters and late side effects in magnetic resonance image-guided adaptive cervical cancer brachytherapy. *Int J Radiat Oncol Biol Phys* 2011;79:356-362.
  69. Kim TH, Kim JY, Sohn DK, et al. A prospective observational study with dose volume parameters predicting rectosigmoidoscopic findings and late rectosigmoid bleeding in patients with uterine cervical cancer treated by definitive radiotherapy. *Radiat Oncol* 2021;3:8:28.
  70. Kirchheiner K, Nout RA, Lindegaard JC, et al. Dose-effect relationship and risk factors for vaginal stenosis after definitive radio (chemo)therapy with image-guided brachytherapy for locally advanced cervical cancer in the EMBRACE study. *Radiother Oncol* 2016;118:160-166.
  71. Manea E, Escande A, Bockel S, et al. Risk of late urinary complications following image guided adaptive brachytherapy for locally advanced cervical cancer: Refining bladder dose-volume parameters. *Int J Radiat Oncol Biol Phys* 2018;101:411-420.
  72. Naik A, Gurjar OP, Gupta KL, et al. Comparison of dosimetric parameters and acute toxicity of intensity-modulated and three-dimensional radiotherapy in patients with cervix carcinoma: A randomized prospective study. *Cancer Radiotherapie* 2016;20:370-376.
  73. Pathy S, Kumar L, Pandey RM, et al. Impact of treatment time on chemoradiotherapy in locally advanced cervical carcinoma. *Asian Pac J Cancer Prev* 2015;16:5075-5079.
  74. Rodriguez-Lopez JL, Ling DC, Keller A, et al. Ureteral stenosis after 3D MRI-based brachytherapy for cervical cancer - Have we identified all the risk factors? *Radiother Oncol* 2021;155:86-92.
  75. Sharma Sr. N, Gupta M, Joseph D, et al. A prospective randomized study of intensity-modulated radiation therapy versus three-dimensional conformal radiation therapy with concurrent chemotherapy in locally advanced carcinoma cervix. *Cureus* 2022;14:e21000.
  76. Wang J, Zhang KS, Liu Z, et al. Using new vaginal doses evaluation system to assess the dose-effect relationship for vaginal stenosis after definitive radio(chemo)therapy for cervical cancer. *Front Oncol* 2022;12 840144.